-+ 0.00%
-+ 0.00%
-+ 0.00%

Abivax to present phase 3 obefazimod ulcerative colitis data at Digestive Disease Week

PUBT·04/22/2026 20:13:24
Listen to the news
Abivax to present phase 3 obefazimod ulcerative colitis data at Digestive Disease Week
  • Abivax flagged nine abstracts on obefazimod from Phase 3 ABTECT program for presentation at Digestive Disease Week 2026 in Chicago on May 2-5, 2026.
  • Data will be presented in future, spanning efficacy, tolerability, patient-reported outcomes, and preclinical antifibrotic activity in inflammatory bowel disease models.
  • Company highlighted improvements seen across histologic and endoscopic assessments, with patient-reported fatigue and quality-of-life gains supporting positioning as a potential new treatment option for moderate-to-severe ulcerative colitis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abivax SA published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: fr_reg_2313426_fr), on April 22, 2026, and is solely responsible for the information contained therein.